FindTrial
Sign In

Temozolomide capsule

DRUG5 trials

Sponsors

European Institute of Oncology, Asan Medical Center, Peking Union Medical College Hospital, Tianjin Medical University Second Hospital, Institute of Cancer Research, United Kingdom

Conditions

Chemotherapy EffectFrailtyGastrointestinal Stromal TumorsGlioblastoma Multiforme (GBM)Malignant Primary GliomasNeuroendocrine TumorsParaganglioma, MalignantPheochromocytoma Malignant

Phase 1

5G-PEARL: Paxalisib in Malignant Brain Tumours
RecruitingNCT07391215
Institute of Cancer Research, United KingdomGlioblastoma Multiforme (GBM), Malignant Primary Gliomas
Start: 2026-01-19End: 2029-06-30Target: 64Updated: 2026-02-05

Phase 2

Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
RecruitingNCT05554003
European Institute of OncologyChemotherapy Effect, Frailty, Neuroendocrine Tumors
Start: 2022-01-14End: 2024-12-31Target: 46Updated: 2024-11-18
The Efficacy and Safety of Temozolomide in SDH-deficient GIST
RecruitingNCT05661643
Asan Medical CenterGastrointestinal Stromal Tumors
Start: 2023-06-28End: 2027-12-31Target: 29Updated: 2024-03-15
The Efficacy and Safety of Temozolomide in Patients With MPPGL
CompletedNCT05858177
Peking Union Medical College HospitalParaganglioma, Malignant, Pheochromocytoma Malignant, Pheochromocytoma, Metastatic
Start: 2019-10-01End: 2023-01-01Updated: 2023-05-15
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
RecruitingNCT06739395
Tianjin Medical University Second HospitalPrecision Medicine, Solid Tumor
Start: 2024-11-01End: 2027-05-01Target: 300Updated: 2024-12-18